Related Experiment Video
Updated: Aug 11, 2026

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
Aldosterone in renal disease
Hassan N Ibrahim1, Thomas H Hostetter
1Division of Renal Diseases and Hypertension, University of Minnesota, Minneapolis 55455, USA. ibrah007@umn.edu
Purpose Of Review:
Interruption of the renin-angiotensin-aldosterone system, chiefly with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, has yielded beneficial results in retarding injury and progression in numerous intrinsic renal diseases. The renoprotection offered by these agents is incomplete and far from optimal. Studying mediators of progression other than angiotensin II is therefore extremely important. The emerging role of aldosterone in progression of renal disease and the utility of its antagonism is discussed here.
Recent Findings:
The experimental evidence linking aldosterone to renal disease is discussed. The exciting results from clinical studies employing mineralocorticoid receptor blockers are also described.
Summary:
Aldosterone antagonism offers additional antiproteinuric benefits to those achieved with angiotensin-converting enzyme inhibition. Long-term trials addressing effectiveness and safety, especially in regards to hyperkalemia, are greatly needed.
Insights
Aldosterone antagonism provides additional benefits beyond current treatments for kidney disease progression. Further long-term studies are needed to confirm its effectiveness and safety, particularly regarding hyperkalemia.
Area of Science:
- Nephrology
- Endocrinology
- Cardiovascular Medicine
Background:
- Renin-angiotensin-aldosterone system (RAAS) inhibitors improve outcomes in intrinsic renal diseases.
- Current RAAS inhibition therapies offer incomplete renoprotection.
- Exploring alternative pathways like aldosterone is crucial for optimal kidney disease management.
Purpose of the Study:
- To review the role of aldosterone in renal disease progression.
- To discuss the therapeutic potential of aldosterone antagonism.
- To evaluate the benefits of mineralocorticoid receptor blockers in nephrology.
Main Methods:
- Review of experimental evidence linking aldosterone to renal pathology.
- Analysis of clinical study results from mineralocorticoid receptor antagonist trials.
Main Results:
- Experimental data support aldosterone's contribution to renal injury.
- Clinical studies demonstrate mineralocorticoid receptor blockers yield significant antiproteinuric effects.
- Aldosterone antagonism complements existing therapies like ACE inhibitors.
Conclusions:
- Aldosterone antagonism offers additional antiproteinuric benefits.
- Further long-term trials are essential to establish efficacy and safety.
- Hyperkalemia risk requires careful monitoring in aldosterone antagonism therapy.
Related Concept Videos
Hormonal Regulation
Antihypertensive Drugs: Potassium-Sparing Diuretics
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Introduction to Urinary System
The kidneys are bean-shaped organs located in the retroperitoneal space, on either side of the vertebral column, between the T12 and L3 vertebrae. They are partially protected by the rib cage and surrounded by perirenal fat, which provides cushioning. They are responsible for urine formation and play critical roles in regulating blood pressure, electrolyte levels, and hormone production. The ureters...
Renal Tubule and Collecting Duct
Proximal Convoluted Tubule (PCT):
The PCT is the initial segment of the renal tubule, extending from the Bowman's capsule that encloses the glomerulus. Its convoluted structure and microvilli-lined cells increase the surface area for reabsorption. The PCT reabsorbs glucose, amino acids, sodium, and water from the filtrate, ensuring essential...

